Citation Information :
Chandrasekaran D, Sundaram S, N K, R P. The role of vascular endothelial growth factor (VEGF) in the diagnosis of renal cell carcinoma. 2016; 4 (1):22-27.
Background: Renal cell carcinoma is the most lethal urological cancer. Most patients present with metastasis. Their treatment is limited as the tumor is chemoresistant and hormone resistant. Vascular Endothelial Growth Factor is the key mediator of angiogenesis in cancer. Inactivation of von Hippel-Lindau gene leads to the production of Hypoxia Inducible Factor-1α. Following this VEGF-A becomes highly expressed in the carcinoma tissue. This results in tumorigenesis by promoting distant metastasis, uncontrolled growth, and resistance to apoptosis.
Aim: The aim of this study was to evaluate the expression of VEGF in renal tumor cells and adjacent normal tissue and to compare the expressions of the marker with the selective risk factors.
Materials and Methods: This study was conducted among 30 cases of histopathologically proven renal cell carcinoma (RCC). Ethical clearance and the necessary permission from the Pathology department of Sri Ramachandra University were obtained. VEGF was analyzed by Biotin Streptavidin Immunoperoxidase method. Q scoring was done.
Results: 90% of cases were VEGF positive in the tumor area, whereas the cells in the adjacent normal tissue area expressed weak staining. The clear cell renal cell carcinoma, a subtype of RCC showed strong and diffuse staining. Comparison of the VEGF Q score with the various risk factors and tumor characteristics was done, but no significant difference was found.
Conclusion: VEGF was strongly expressed in clear cell renal cell carcinoma tissue. VEGF could play a role as a potential diagnostic marker in renal cell carcinoma and could help in assessing prognosis and designing therapy.
Motzer R, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger G.B et al. Kidney cancer, Version 2. 2014. Journal of the National Comprehensive Cancer Network 2014;12(2):175-182.
Garcia J, Rini B. Recent Progress in the Management of Advanced Renal Cell Carcinoma. CA: A Cancer Journal for Clinicians. 2007;57(2):112-125
Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986;77(2):351-356
Semenza G. Vascular Responses to Hypoxia and Ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2009;30(4):648-652.
Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathology. 1993;143(5): 1255-1262.
Klatte T, Seligson D, Riggs S, Leppert J, Berkman M, Kleid M et al. Hypoxia-Inducible Factor 1 in Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2007;13(24):7388-7393.
Djordjevic G, Mozetic V, Mozetic D, Licul V, Ilijas K, Mustac E et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathology - Research and Practice. 2007;203(2):99-106.
Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
Aslam S. Eisen T. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol. 2013;5(6):324-333.
Minnardi D, Santoni M, Lucarini G, Mazzucchelli R, Burattini L, Conti A et al. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urologic oncology: seminars and original investigations 2014; 1-7
Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol. 2004;202(3):265-273.
Protzel C, Maruschke M, Hakenberg OW. Epidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma. European Urology Supplements 2012;11(3):52-59.
Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93(3):297-302.
Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35(1):133-137.
Fujita N, Okegawa T, Terado Y, Tambo M, Higashihara E, Nutahara K. Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Research Notes. 2014;7(1):369.
